<div id="readability-page-1"><div>Mersana Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mersana Therapeutics, Inc. - MRSN Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick &amp; Foti, LLC (“KSF”) are investigating the proposed sale of Mersana Therapeutics, Inc. (NasdaqGS: MRSN) to Day One Biopharmaceuticals, Inc. Under the terms of the proposed transaction, shareholders of Mersana will receive $25.00 per share in cash plus one non-tradable contingent value right (CVR) per share to receive certain potential milestone payments of up to $30.25 per CVR in cash, for total consideration of up to $55.25 per share in cash. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-mrsn/ to learn more. Please note that the transaction is structured as a tender offer, such that time may be of the essence. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com. CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn <img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNTExMTY3MDU5NTByMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNTExMTY3MDU5NTByMQ"/> Kahn Swick &amp; Foti, LLC Lewis Kahn, Managing Partner lewis.kahn@ksfcounsel.com 1-877-515-1850 1100 Poydras St., Suite 960 New Orleans, LA 70163 View source version on businesswire.com: https://www.businesswire.com/news/home/20251116705950/en/</div></div>

MRSN

Kahn Swick & Foti, LLC，由前路易斯安那州检察长 Charles C. Foti, Jr.领导，正在调查 Mersana Therapeutics, Inc.拟议出售给 Day One Biopharmaceuticals, Inc.的事宜。调查重点是每股 25 美元现金报价及潜在里程碑付款的合理性，总计可达每股 55.25 美元。如果股东认为该交易低估了公司，鼓励他们联系 KSF

Mersana Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mersana Therapeutics, Inc. - MRSN

路易斯安那州前总检察长发布 Mersana Therapeutics 投资者警报：Kahn Swick & Foti, LLC 正在调查 Mersana Therapeutics, Inc.拟议出售中的价格和流程是否合理 - MRSN